The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein

Human minor histocompatibility Ags (mHag) present significant barriers to successful bone marrow transplantation. However, the structure of human mHag and the basis for antigenic disparities are still largely unknown. Here we report the identification of the gene encoding the human mHag HA-2 as a previously unknown member of the class I myosin family, which we have designated MYO1G. The gene is located on the short arm of chromosome 7. Expression of this gene is limited to cells of hemopoietic origin, in keeping with the previously defined tissue expression of the HA-2 Ag. RT-PCR amplification of MYO1G from different individuals led to the identification of two genetic variants, designated MYO1GV and MYO1GM. The former encodes the peptide sequence previously shown to be the HA-2 epitope (YIGEVLVSV), whereas the latter shows a single amino acid change in this peptide (YIGEVLVSM). This change has only a modest effect on peptide binding to the class I MHC-restricted element HLA-A*0201, and a minimal impact on recognition by T cells when added exogenously to target cells. Nonetheless, as detected using either T cells or mass spectrometry, this amino acid change results in a failure of the latter peptide to be presented at the surface of cells that express MYO1GM endogenously. These studies have thus identified a new mHag-encoding gene, and thereby provide additional information about both the genetic origins of human mHag as well as the underlying basis of an Ag-positive vs Ag-negative state.

[1]  S. Karthickeyan Gene Mapping by Fluorescence In situ Hybridization (Fish) in Cattle and Buffaloes , 2002 .

[2]  J. Shabanowitz,et al.  The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing , 2001, The Journal of experimental medicine.

[3]  S. Carr,et al.  Mass Spectrometry in Biology & Medicine , 2000, Humana Press.

[4]  J. Shabanowitz,et al.  Subfemtomole MS and MS/MS peptide sequence analysis using nano-HPLC micro-ESI fourier transform ion cyclotron resonance mass spectrometry. , 2000, Analytical chemistry.

[5]  V. Engelhard,et al.  The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice1 , 2000, The Journal of Immunology.

[6]  J. Shabanowitz,et al.  Sequencing the Primordial Soup , 2000 .

[7]  J. Shabanowitz,et al.  Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. , 1999, Journal of immunology.

[8]  F. Locatelli,et al.  Resolution of immune haemolytic anaemia with allogeneic bone marrow transplantation after an unsuccessful autograft , 1999, British journal of haematology.

[9]  S Uebel,et al.  Specificity of the proteasome and the TAP transporter. , 1999, Current opinion in immunology.

[10]  R. Verdijk,et al.  Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.

[11]  Bin Wang,et al.  Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Smith,et al.  Bone marrow transplantation for autoimmune diseases. , 1999, Current opinion in oncology.

[13]  J. Shabanowitz,et al.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.

[14]  V. Mermall,et al.  Unconventional myosins in cell movement, membrane traffic, and signal transduction. , 1998, Science.

[15]  A. Marmont Stem cell transplantation for severe autoimmune diseases: progress and problems. , 1998, Haematologica.

[16]  L. Eisenlohr,et al.  Murine Transporter Associated with Antigen Presentation (TAP) Preferences Influence Class I–restricted T Cell Responses , 1997, The Journal of experimental medicine.

[17]  S Uebel,et al.  Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Goulmy Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[19]  J. Snowden,et al.  Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin’s lymphoma , 1997, Bone Marrow Transplantation.

[20]  A. Marmont Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. , 1997, The Journal of rheumatology. Supplement.

[21]  R. A. Myers,et al.  Gene mapping by fluorescence in situ hybridization. , 1996 .

[22]  A Sette,et al.  The peptide-binding motif for the human transporter associated with antigen processing , 1995, The Journal of experimental medicine.

[23]  F Koning,et al.  Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.

[24]  M. Feltkamp,et al.  Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. , 1995, Journal of immunology.

[25]  M. Mooseker,et al.  Cloning and mRNA expression of human unconventional myosin-IC. A homologue of amoeboid myosins-I with a single IQ motif and an SH3 domain. , 1994, Journal of molecular biology.

[26]  T. Hasson,et al.  Identification and overlapping expression of multiple unconventional myosin genes in vertebrate cell types. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Günter J. Hämmerling,et al.  Selectivity of MHC-encoded peptide transporters from human, mouse and rat , 1994, Nature.

[28]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[29]  A. Bakker,et al.  Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. , 1992, Journal of immunology.

[30]  E. Goulmy,et al.  Minor histocompatibility antigens, defined by graft‐vs.‐host disease‐derived cytotoxic T lymphocytes, show variable expression on human skin cells , 1991, European journal of immunology.

[31]  H. Rammensee,et al.  Identification of classical minor histocompatibility antigen as cell-derived peptide , 1990, Nature.

[32]  L. Sherman,et al.  Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response , 1989, The Journal of experimental medicine.

[33]  P. Parham,et al.  Cytotoxic T lymphocyte-defined epitope differences between HLA-A2.1 and HLA-A2.2 map to two distinct regions of the molecule. , 1988, Journal of immunology.

[34]  M. Daha,et al.  Endothelial cell lysis induced by lymphokine‐activated human peripheral blood mononuclear cells , 1987, European journal of immunology.

[35]  S. Spicer,et al.  Tissue culture of human kidney epithelial cells of proximal tubule origin. , 1984, Kidney international.

[36]  P. Parham,et al.  Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. , 1981, Human immunology.

[37]  M. C. Green,et al.  Catalog of mutant genes and polymorphic loci. , 1981 .

[38]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.